ArticleCancer science2004
Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers.
Article in Cancer science, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.
- Wnt signaling in ovarian tumorigenesis.International journal of gynecological cancer : official journal of the International Gynecological Cancer SocietyPooled it
- Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2016Trial
- Safely Targeting Cancer, the Wound That Never Heals, Utilizing CBP/Beta-Catenin Antagonists.Cancers · 2025Article
- Current data and future perspectives on DNA methylation in ovarian cancer (Review).International journal of oncology · 2024Review
- The role of DNA methylation in ovarian cancer chemoresistance: A narrative review.Health science reports · 2023Article
- Extracellular matrix-based gene signature for predicting prognosis in colon cancer and immune microenvironment.Translational cancer research · 2023Article
- Taking the road less traveled - the therapeutic potential of CBP/β-catenin antagonists.Expert opinion on therapeutic targets · 2021Review
- Evaluation of the Diagnostic Potential of Candidate Hypermethylated Genes in Epithelial Ovarian Cancer in North Indian Population.Frontiers in molecular biosciences · 2021Article
- Wnt Signaling in Ovarian Cancer Stemness, EMT, and Therapy Resistance.Journal of clinical medicine · 2019Review
- Prognostic Relevance of SFRP1 Gene Promoter Methylation in Colorectal CarcinomaAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Methylation-reprogrammed Wnt/β-catenin signalling mediated prenatal hypoxia-induced brain injury in foetal and offspring rats.Journal of cellular and molecular medicine · 2018Article
- Application of multiplex methylated-specific PCR with capillary electrophoresis to explore prognostic value of TSGs hypermethylation for hepatocellular carcinoma.Journal of clinical laboratory analysis · 2018Article
- Dicer promotes tumorigenesis by translocating to nucleus to promote SFRP1 promoter methylation in cholangiocarcinoma cells.Cell death & disease · 2017Article
- Expression and prognostic value of SFRP1 and β-catenin in patients with glioblastoma.Oncology letters · 2016Article
- Functional analyses and prognostic significance of SFRP1 expression in bladder cancer.Journal of cancer research and clinical oncology · 2015Article
- Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.Molecular cancer · 2014Article
- Can we safely target the WNT pathway?Nature reviews. Drug discovery · 2014Review
- Secreted frizzled related protein 1 modulates taxane resistance of human lung adenocarcinoma.Molecular medicine (Cambridge, Mass.) · 2014Article
- The Wnt antagonist sFRP1 as a favorable prognosticator in human biliary tract carcinoma.PloS one · 2014Article
- A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population.Frontiers in oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The SFRP1 gene on chromosome 8p11.2 encodes a Wnt signaling antagonist, and was recently demonstrated to be a new tumor suppressor that is inactivated by promoter methylation in human colon cancers. Here, we analyzed promoter methylation of the SFRP1 gene in human ovarian cancers, in which loss of heterozygosity in 8p is frequently observed and involvement of the Wnt signaling pathway has been suggested. Methylation-specific PCR (MSP) analysis showed that four of 13 ovarian cancer cell lines and two of 17 primary ovarian cancers had methylated SFRP1, while an immortalized ovarian epithelial cell line, HOSE, and seven ovarian endometrial cyst samples did not. In the four ovarian cancer cell lines with the methylation, SFRP1 was not expressed at all as determined by quantitative RT-PCR analysis. A cell line with SFRP1 methylation, MCAS, was treated with a demethylating agent, 5-aza-2'-deoxycytidine, and demethylation of the promoter and re-expression of SFRP1 were observed. These results show that SFRP1 is inactivated by promoter methylation in human ovarian cancers, as well as colon cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.